Max Mamonkin

Engineering T cell therapies for cancer and chronic diseases | @Columbia Institute for Cell Engineering and Therapy (CICET)

[Heczey Lab @HeczeyLab]

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
https://t.co/ybNobLrQvy

[MalmbergLab @MalmbergLab]

A cell intrinsic NKG2A/C switch receptor to overcome the critical HLA-E checkpoint. Fun collaboration with the Michel Sadelain lab. Michelle Sætersmoen, Ivan Kotchetkov, @LambertoTR @CoE_PRIMA @UniOslo_MED @Oslounivsykehus @CIM_Sweden

[Justin A. Guerrero @dr_jguerrero]

I am very pleased to announce the work I did as a graduate student in the labs of Crystal Mackall and Everett Meyer has been published in Nature Communications, open access! https://t.co/E79Xyrp761

[Columbia Medicine @ColumbiaMed]

Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center.

➡️https://t.co/g8OhtIBMxG

[Peggy Goodell @Goodell_Lab]

Recruiting faculty to the Dept of Molecular and Cellular Biology at Baylor College of Medicine in Houston, TX! Recruiting broadly in cancer and cell biology. Submit by October 1, 2024, for full review. #cellbio @BCMhouston
https://t.co/4sLzKsOxzD

https://t.co/4Q9xpXvcbI

[Max Mamonkin @MaxMamonkin]

@dlwagner13 Very cool!

[Dimitrios L. Wagner @dlwagner13]

Preprint alert 🚨

Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐

Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells

https://t.co/76xEoKTGsr

🧵👇

[Michael Birnbaum @MEBirnbaum]

My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. https://t.co/F5fyVKSsTs

[Max Mamonkin @MaxMamonkin]

@may_daher @ScienceTM Well done, May & team

[Max Mamonkin @MaxMamonkin]

Great step forward in humanized mouse models. Using iPSC-derived CD34+ iHSC which engraft and produce human multi-lineage progeny in immunodeficient NBSGW mice
https://t.co/eJ7QpSkW3P

[Max Mamonkin @MaxMamonkin]

An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast.
https://t.co/t4ARJc7TtB

[Max Mamonkin @MaxMamonkin]

Excellent results with autologous CD7-PEBL CART in T-ALL from Singapore and Rome https://t.co/0yH3NEBMuD

[Max Mamonkin @MaxMamonkin]

@jaehyukchoimd Yeah CD5 is known to internalize quickly upon binding to an antibody, which was used in the 90s with ADC. But CD5 internalization speed/extent depends on the targeted epitope and may not work with all CARs. Also CD7 and other Ag don't behave the same way

[Max Mamonkin @MaxMamonkin]

T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma:
https://t.co/MgxE1qNDB1

[Paul Maciocia @paulmaciocia]

The genomic basis of childhood T-lineage acute lymphoblastic leukaemia | Nature https://t.co/522oG5RnXg

[Marco Ruella @MarcoRuella]

Congrats to the now Dr. @_ruchipatel
for the publication of her PhD thesis in @SciImmunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. @PennMedicine @RuellaLab https://t.co/7AaIl4GSYN

[Nathan Singh @NathanSinghLab]

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! https://t.co/0w65w7slnJ (1/4)

[MalmbergLab @MalmbergLab]

Comprehensive thread highlighting our most recent work now out in @CellStemCell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing @QuirinHammer and @KarloPerica. @CoE_PRIMA, @Oslounivsykehus @UniOslo_MED @karolinskainst

[Max Mamonkin @MaxMamonkin]

Limiting institutional overhead on NIH grants?

[John Arnold @johnarnold]

Paragraph tucked into House NIH funding bill to limit indirects makes research $ go further and attacks administrative bloat at wealthy colleges. Proposal caps indirects at 30% rather than reimbursing at a school's actual overhead rate. Current policy encourages wasteful spending at universities; this bill creates a powerful incentive to control costs.
via @stuartbuck1

[Max Mamonkin @MaxMamonkin]

@DrPHanley Awesome news, Pat. Congratulations to you both!